Understanding the Mystery Behind Certain People's Immunity to Popular Diabetes Drugs
About one in ten people carry genetic variants that cause a unique condition known as GLP-1 resistance. This condition is characterized by higher than usual levels of the hormone GLP-1 (glucagon-like peptide-1), which usually helps control blood sugar. However, in people with GLP-1 resistance, this hormone seems less effective.
What remains a mystery is whether these genetic variants affect the success of weight loss treatments using GLP-1 drugs. These medicines are becoming more common in the fight against obesity and are usually given in higher doses for weight loss than for diabetes treatment.
A Decade-Long Investigation into GLP-1 Resistance
The research, which took ten years and included both human and mouse studies, as well as analysis of clinical trial data, aimed to understand how these drugs affect blood sugar levels.
During the trials, it was observed that individuals carrying these specific genetic variants couldn't lower their blood sugar levels effectively even after six months of treatment. This would typically prompt a doctor to change the patient's medication. Knowing who is likely to respond positively could help patients receive the right medicine sooner. This approach could be a step toward precision medicine.
The Role of PAM Gene Variants in GLP-1 Resistance
The researchers focused their investigation on two specific genetic variants that influence an enzyme named PAM (peptidyl-glycine alpha-amidating monooxygenase). This enzyme has a unique role in activating many hormones in the body, including GLP-1.
Previous studies had shown that PAM variants are more common in people with diabetes and can hinder insulin release from the pancreas. The researchers aimed to understand whether these variants also disrupt the function of GLP-1, a hormone produced in the gut that helps control blood sugar after meals by stimulating insulin release, slowing stomach emptying, and reducing the appetite. GLP-1 receptor agonist drugs are designed to mimic this hormone.
Contradicting Assumptions and Confirming Findings
Initial assumptions suggested that individuals with the PAM variant would have lower GLP-1 levels, possibly because the hormone would be less stable without proper processing. However, the actual findings were surprising. Individuals with the PAM variant had higher GLP-1 levels, which contradicted the researchers' initial expectations.
Despite people with the PAM variant having higher circulating levels of GLP-1, there was no evidence of higher biological activity. They were not reducing their blood sugar levels more quickly. More GLP-1 was needed to have the same biological effect, indicating they were resistant to GLP-1.
Because the results were unexpected, the researchers spent several years verifying them through multiple approaches. They also studied mice lacking the PAM gene. These animals showed similar signs of GLP-1 resistance, with elevated hormone levels that failed to improve blood sugar control.
Implications of GLP-1 Resistance on Diabetes Treatment
To understand the impact of GLP-1 resistance on treatment outcomes, the team analyzed data from several clinical trials involving people with diabetes. They found that individuals with PAM variants responded less effectively to GLP-1 drugs and were less likely to reach target HbA1c levels, a measure of long-term blood sugar control.
Importantly, these genetic variants did not affect how patients responded to other common diabetes medications. This finding suggests that the resistance is specific to medications that work through GLP-1 receptor pharmacology.
The Road Ahead: Unraveling the Biological Puzzle
The biological cause of GLP-1 resistance remains unclear and is likely influenced by multiple factors. However, this doesn't mean that progress isn't being made. Despite not fully understanding insulin resistance, effective treatments for this condition have been developed over decades of research.
There is hope that similarly effective treatments can be developed for GLP-1 resistance. The possibility of creating medications that sensitize people to GLP-1, or finding formulations of GLP-1 that avoid resistance, is an exciting prospect for the future of diabetes and obesity treatment.